Director Isaac Manke filed a Form 4 with the SEC on November 13, 2026, reporting the acquisition of 942,854 stock options in Addex Therapeutics Ltd. (NASDAQ:ADXN) on November 11, 2026.
Key Highlights
- Transaction date: November 11, 2026, with 942,854 stock options (right to buy) acquired by Director Isaac Manke.
- Exercise price: $0.026 per option, reflecting a conversion from CHF to USD at a rate of $1.1995 per CHF 1.00 as of November 11, 2026.
- Vesting schedule: Options vest in equal monthly installments over a 4-year period beginning at the exercisable date of November 11, 2026.
- Expiration date: November 10, 2036, with each option granting the right to purchase one ADXN share listed on SIX Swiss Exchange.
- Price of derivative security: $0, as reported in the filing.
- Total derivative securities beneficially owned following the transaction: 992,854, held directly.
Isaac Manke's November 2026 Option Grant at Addex Therapeutics
According to the Form 4 filed on November 13, 2026, Isaac Manke, a director of Addex Therapeutics Ltd. (NASDAQ:ADXN), reported the acquisition of 942,854 stock options on November 11, 2026. The filing identifies the transaction code as "A," indicating an acquisition. Each option carries an exercise price of $0.026, which the filing states "reflects the conversion from CHF to USD at an exchange rate of $1.1995 per CHF 1.00 as of November 11, 2026."
The filing discloses that the options vest "in equal monthly installments over a 4-year period beginning at the exercisable date," which is listed as November 11, 2026. The expiration date for these options is November 10, 2036. The underlying security is common stock, and each option grants the right to purchase one ADXN share listed on the SIX Swiss Exchange. The price of the derivative security is reported as $0.
Following this transaction, the filing reports that Manke beneficially owns 992,854 derivative securities in total, held directly. The Form 4 was signed by Lenaic Nathanael Teyssedou by power of attorney and dated November 13, 2026. No transactions were reported in Table I covering non-derivative securities.
What Was Disclosed
Addex Therapeutics director Isaac Manke reported acquiring 942,854 stock options on November 11, 2026, at an exercise price of $0.026, vesting monthly over four years, with an expiration of November 10, 2036, bringing total beneficial ownership of derivative securities to 992,854.




Please wait processing your request...